Jefferies Maintains a Buy Rating on Merck & Co. (MRK), Keeps the PT Unchanged

Merck & Co., Inc. (NYSE:MRK) is one of the 10 Best and Cheap Stocks to Buy Now. On June 18, Akash Tewari, an analyst from Jefferies, maintained the Buy rating on Merck & Co., Inc. (NYSE:MRK) with a price target of $138. The positive outlook is based on the stability of the company’s vaccine sales and the anticipated launch of a subcutaneous version of Keytruda.

There had been some speculations regarding the change in the number of vaccine doses by The Advisory Committee on Immunization Practices. This concerned Merck & Co., Inc. (NYSE:MRK) as a reduction in the number of Gardasil doses could have resulted in lower sales and vaccine revenue. However, analyst Akash Tewari noted that the upcoming ACIP meeting agenda does not include a discussion on HPV vaccine, implying that the speculated change is not coming anytime soon.

Moreover, Tewari anticipates the sooner-than-expected introduction of a subcutaneous version of Keytruda. The analyst believes that this will enable Merck & Co., Inc. (NYSE:MRK) to capture a greater market share and will drive the company’s revenue higher.

Merck & Co., Inc. (NYSE:MRK) is an international healthcare company that develops and sells prescription medicine, vaccines, and animal health products. It operates through two main segments including the Pharmaceutical and Animal Health Segment.

While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.